Food and Drug Administration, 2021 ), was associated with adverse ovarian effects when administered to sexually immature monkeys, including a decrease or absence of secondary and tertiary ovarian follicles; these effects showed a trend toward recovery after the end of treatment.
← all excerpts
Gonadotoxicity of immunotherapy and targeted agents in patients with cancer and impact on subsequent pregnancies.
1
—
—